BRPI0707334A8 - formulação de cápsula de gelatina mole e método para estabilização de um composto 15-ceto-prostaglandina - Google Patents

formulação de cápsula de gelatina mole e método para estabilização de um composto 15-ceto-prostaglandina

Info

Publication number
BRPI0707334A8
BRPI0707334A8 BRPI0707334A BRPI0707334A BRPI0707334A8 BR PI0707334 A8 BRPI0707334 A8 BR PI0707334A8 BR PI0707334 A BRPI0707334 A BR PI0707334A BR PI0707334 A BRPI0707334 A BR PI0707334A BR PI0707334 A8 BRPI0707334 A8 BR PI0707334A8
Authority
BR
Brazil
Prior art keywords
keto
gelatin capsule
soft gelatin
stabilizing
compound
Prior art date
Application number
BRPI0707334A
Other languages
English (en)
Inventor
Hirata Ryu
Ueno Ryuji
Harada Yasuhiro
Hashitera Yukiko
Original Assignee
R Tech Ueno Ltd
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38169220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0707334(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by R Tech Ueno Ltd, Sucampo Ag filed Critical R Tech Ueno Ltd
Publication of BRPI0707334A2 publication Critical patent/BRPI0707334A2/pt
Publication of BRPI0707334A8 publication Critical patent/BRPI0707334A8/pt
Publication of BRPI0707334B1 publication Critical patent/BRPI0707334B1/pt
Publication of BRPI0707334B8 publication Critical patent/BRPI0707334B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

formulação de cápsula de gelatina mole e método para estabilização de um composto 15-ceto-prostaglandina. a presente invenção refere-se a uma formulação de cápsula de gelatina mole de um composto 1 5-ceto-prostaglandina, a qual compreende: um invólucro de cápsula de gelatina mole e álcool de açúcar como um plastificante, e uma mistura compreendendo um composto 15-ceto-prostaglandina e um veículo farmaceuticamente aceitável enche o invólucro. através da encapsulação do composto 1 5-ceto-prostaglandina no invólucro de cápsula de gelatina mole especificado, a estabilidade do composto é significantemente aperfeiçoada.
BRPI0707334A 2006-01-24 2007-01-23 formulação de cápsula de gelatina mole de um composto 15-ceto-prostaglandina e método para estabilização do um composto 15-cetoprostaglandina BRPI0707334B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76136006P 2006-01-24 2006-01-24
US60/761,360 2006-01-24
PCT/JP2007/051329 WO2007086536A2 (en) 2006-01-24 2007-01-23 Soft-gelatin capsule formulation

Publications (4)

Publication Number Publication Date
BRPI0707334A2 BRPI0707334A2 (pt) 2011-05-03
BRPI0707334A8 true BRPI0707334A8 (pt) 2018-04-10
BRPI0707334B1 BRPI0707334B1 (pt) 2021-02-23
BRPI0707334B8 BRPI0707334B8 (pt) 2021-05-25

Family

ID=38169220

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0707334A BRPI0707334B8 (pt) 2006-01-24 2007-01-23 formulação de cápsula de gelatina mole de um composto 15-ceto-prostaglandina e método para estabilização do um composto 15-cetoprostaglandina

Country Status (16)

Country Link
US (4) US8026393B2 (pt)
EP (1) EP1978944B1 (pt)
JP (1) JP4783794B2 (pt)
KR (1) KR101393944B1 (pt)
CN (3) CN104983712A (pt)
AU (1) AU2007208632B2 (pt)
BR (1) BRPI0707334B8 (pt)
CA (1) CA2637274C (pt)
DK (1) DK1978944T3 (pt)
ES (1) ES2392590T3 (pt)
IL (1) IL192867A (pt)
MX (1) MX2008009650A (pt)
NZ (1) NZ570191A (pt)
PT (1) PT1978944E (pt)
RU (1) RU2420291C3 (pt)
WO (1) WO2007086536A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008009650A (es) * 2006-01-24 2008-11-06 R Tech Ueno Ltd Formulacion de capsula de gelatina suave.
EP2327398A3 (en) 2007-07-19 2014-05-21 R-Tech Ueno, Ltd. Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound
RU2465916C2 (ru) 2007-10-19 2012-11-10 Оцука Фармасьютикал Ко., Лтд. Твердый фармацевтический препарат матричного типа
AU2010295464B2 (en) * 2009-09-18 2015-11-26 Merck Sharp & Dohme Corp. Use of opioid receptor antagonist for gastrointestinal tract disorders
CA2779736A1 (en) 2009-11-03 2011-05-12 Bernard Charles Sherman Stable pharmaceutical formulations comprising lubiprostone
US20120277299A1 (en) * 2011-04-27 2012-11-01 Sucampo Ag Method for modulating ion transporter
JP6273261B2 (ja) 2012-04-30 2018-01-31 ダウ アグロサイエンシィズ エルエルシー 有害生物防除剤組成物送達ビヒクル
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
ES2787220T3 (es) 2015-03-26 2020-10-15 Patheon Softgels Inc Cápsulas blandas llenas de líquido
US9808531B2 (en) 2015-09-22 2017-11-07 Graybug Vision, Inc. Compounds and compositions for the treatment of ocular disorders
CN107638403B (zh) * 2016-07-22 2020-05-05 江苏威凯尔医药科技有限公司 一种硬胶囊制剂
JP6957610B2 (ja) 2016-10-06 2021-11-02 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 医薬品用途のための多層ビーズ
GB201711157D0 (en) * 2017-07-11 2017-08-23 Univ Liverpool Sulfur-Doped Carbonaceous porous materials
CN108619107A (zh) * 2018-05-28 2018-10-09 青海制药厂有限公司 一种含鲁比前列酮的软胶囊及其制备方法
JP7678698B2 (ja) * 2020-04-21 2025-05-16 東和薬品株式会社 ルビプロストンを含む軟カプセル剤及びその製造方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4543353A (en) * 1981-11-27 1985-09-24 Farmitalia Carlo Erba S.P.A. Ester and amide derivatives of 13,14-didehydro prostaglandins
GB8305693D0 (en) * 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
US4755531A (en) * 1986-08-11 1988-07-05 Syntex (U.S.A.) Inc. Thiol esters of 4,5-allenyl prostaglandins and use thereof as antigastric secretion agents
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5225439A (en) * 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5428062A (en) 1987-01-28 1995-06-27 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
CA1324129C (en) 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5591887A (en) 1987-04-30 1997-01-07 R-Tech Ueno, Ltd. Prostaglandins of the F series
DE3853493T2 (de) 1987-05-28 1995-07-27 Kuraray Co Superoxid-Dismutase-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel.
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
US5048022A (en) * 1989-08-01 1991-09-10 Digital Equipment Corporation Memory device with transfer of ECC signals on time division multiplexed bidirectional lines
ATE121624T1 (de) * 1989-08-09 1995-05-15 Ueno Seiyaku Oyo Kenkyujo Kk Verwendung von prostansäurederivaten zur herstellung von arzneimitteln zur verbesserung der ausscheidung von nichtprotein in die därme.
US5254588A (en) 1989-11-22 1993-10-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
JPH07100655B2 (ja) * 1990-04-04 1995-11-01 株式会社アールテック・ウエノ 白内障処置剤
TW224942B (pt) 1990-04-04 1994-06-11 Adka Ueno Kk
ATE174221T1 (de) 1990-05-01 1998-12-15 R Tech Ueno Ltd Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
JPH04187637A (ja) * 1990-11-21 1992-07-06 Ueno Seiyaku Oyo Kenkyusho:Kk 記憶改善剤
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
WO1997047595A1 (en) 1996-06-10 1997-12-18 R-Tech Ueno, Ltd. Endothelin antagonist
US5998438A (en) * 1996-11-26 1999-12-07 Allelix Biopharmaceuticals, Inc. 5-cyclo indole compounds
US6207699B1 (en) * 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
BRPI0014869B8 (pt) 1999-10-15 2021-05-25 Sucampo Ag prostaglandinas bicíclicas, composições estabilizadas das mesmas, bem como processo para sua estabilização
RU2003125876A (ru) * 2001-02-22 2005-02-10 Оно Фармасьютикал Ко., Лтд. (Jp) Лекарственная композиция, включающая диклофенак и орнопростил
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
DE602004030245D1 (de) * 2003-07-03 2011-01-05 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
CN1257711C (zh) * 2003-12-05 2006-05-31 石药集团中奇制药技术（石家庄）有限公司 丁苯酞软胶囊及其制备工艺
JP5265369B2 (ja) * 2006-01-24 2013-08-14 株式会社アールテック・ウエノ 二環式化合物を含む医薬組成物およびその二環式化合物の安定化方法
MX2008009650A (es) * 2006-01-24 2008-11-06 R Tech Ueno Ltd Formulacion de capsula de gelatina suave.
EP2327398A3 (en) * 2007-07-19 2014-05-21 R-Tech Ueno, Ltd. Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound

Also Published As

Publication number Publication date
MX2008009650A (es) 2008-11-06
BRPI0707334B1 (pt) 2021-02-23
KR101393944B1 (ko) 2014-05-12
CN101410097A (zh) 2009-04-15
CA2637274A1 (en) 2007-08-02
US20110300211A1 (en) 2011-12-08
JP2008534432A (ja) 2008-08-28
CA2637274C (en) 2013-06-04
DK1978944T3 (da) 2012-11-05
US20140287036A1 (en) 2014-09-25
BRPI0707334B8 (pt) 2021-05-25
NZ570191A (en) 2010-09-30
CN104971056A (zh) 2015-10-14
RU2008134489A (ru) 2010-02-27
EP1978944A2 (en) 2008-10-15
JP4783794B2 (ja) 2011-09-28
AU2007208632B2 (en) 2012-01-19
US8779187B2 (en) 2014-07-15
ES2392590T3 (es) 2012-12-12
AU2007208632A1 (en) 2007-08-02
CN104983712A (zh) 2015-10-21
BRPI0707334A2 (pt) 2011-05-03
PT1978944E (pt) 2012-11-26
IL192867A (en) 2015-06-30
US20130078303A1 (en) 2013-03-28
RU2420291C2 (ru) 2011-06-10
IL192867A0 (en) 2009-02-11
US20070172523A1 (en) 2007-07-26
WO2007086536A3 (en) 2007-11-15
US8026393B2 (en) 2011-09-27
WO2007086536A2 (en) 2007-08-02
US8338639B2 (en) 2012-12-25
KR20080090526A (ko) 2008-10-08
EP1978944B1 (en) 2012-08-15
RU2420291C3 (ru) 2020-07-21

Similar Documents

Publication Publication Date Title
BRPI0707334A8 (pt) formulação de cápsula de gelatina mole e método para estabilização de um composto 15-ceto-prostaglandina
EA200901319A1 (ru) Композиции для назального введения
UA94942C2 (ru) Фармацевтические композиции с ингибиторами dpp iv
MY174001A (en) Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof
UA105766C2 (uk) Фармацевтична композиція, яка містить сіль стронцію, вітамін d і циклодекстрин
ECSP11004868A (es) Capsulas para inhalación
BRPI0923702B8 (pt) Composições inseticidas estáveis compreendendo spinosin e uma mistura esteroisomérica de sulfoxaflor, e seu método de produção
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
SV2008003106A (es) Composicion farmaceutica estable que contiene docetaxel y un metodo para fabricarla
CY1122416T1 (el) Φαρμακα τα οποια περιεχουν κρυσταλλικες τροποποιησεις (1r,2r)-3-(3-δimeθyλamino-1-αιθυλο-2-μεθυλο-προπυλο)-φαινολης
BR112012026596A2 (pt) método para preparar composições farmacêuticas pretendidas para administração oral compreendendo um ou mais ingredientes ativos e as composições que compreendem as mesmas
UA102254C2 (ru) Жидкий состав для деферипрона с приятным вкусом
EA201290985A1 (ru) Пероральные ветеринарные фармацевтические и нутрицевтические композиции
NO20064262L (no) Fast formulering av ospemifen
UA101407C2 (ru) Стабильная комбинированная фармацевтическая композиция амлодипина и бисопролола фумарат
MX2009012782A (es) Formulaciones para administracion oral de agentes terapeuticos y metodos relacionados.
UA122762C2 (uk) Пероральна композиція 9-[(2,2-диметилпропіламіно)-метил]-міноцикліну або його солі, тверда пресована дозована форма, композиція для ін'єкцій, застосування та спосіб приготування фармацевтичної композиції
DK1746980T3 (da) Farmaceutisk doseringsform omfattende pellets såvel som deres fremstillingsfremgangsmåde
BRPI0418283A (pt) formulação de liberação prolongada e processo para a preparação de uma formulação de liberação prolongada
EA201270573A1 (ru) Гранулированный в расплаве цинакальцет
NO20082181L (no) Formuleringer av Fispemifen
BR122016006880B8 (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
BRPI0511466A (pt) agonistas peptìdicos do receptor de vasopressina
WO2007086541A3 (en) Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: R - TECH UNEO, LTD. (JP) , SUCAMPO AG (CH)

Free format text: TRANSFERIDO PARTE DOS DIREITOS DE: R-TECH UENO, LTD.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/01/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF